Edwards Lifesciences files 8-K with Q3 2025 financial results

Rhea-AI Filing Summary

Edwards Lifesciences (EW) furnished a press release announcing its financial results for the third quarter of 2025. The disclosure was made via Form 8-K under Item 2.02.

The press release is included as Exhibit 99.1 and the information is being furnished, not deemed filed, under the Exchange Act.

0001099800false00010998002025-10-302025-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 30, 2025

EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

1-15525

36-4316614

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

One Edwards Way

Irvine, California 92614

(Address of principal executive offices and zip code)

(949) 250-2500

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $1.00 per share			EW			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.                                      Results of Operations and Financial Condition.

On October 30, 2025, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference.

The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.

Item 9.01.                                      Financial Statements and Exhibits.

			(d)			Exhibits
			99.1			Press release, dated October 30, 2025, reporting Edwards’ financial results for the third quarter of 2025.
			104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 30, 2025
			EDWARDS LIFESCIENCES CORPORATION
			By:			/s/ Scott B. Ullem
						Scott B. Ullem
						Chief Financial Officer

3

Exhibit Index

Exhibit Number						Description
99.1						Press release, dated October 30, 2025, reporting Edwards’ financial results for the third quarter of 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

4

FAQ

What did Edwards Lifesciences (EW) announce in this filing?

The company furnished a press release reporting its financial results for the third quarter of 2025.

Which SEC form did EW use for this disclosure?

Form 8-K.

Which item of Form 8-K covers this disclosure for EW?

Item 2.02, Results of Operations and Financial Condition.

Where can I find the full Q3 2025 results details for EW?

In Exhibit 99.1 attached to the filing.

Is the information in this EW 8-K considered filed or furnished?

It is furnished and not deemed filed under the Exchange Act.

What is Edwards Lifesciences’ trading symbol and exchange?

Symbol EW on the New York Stock Exchange.

What additional exhibit is included with this 8-K?

Exhibit 104, the Cover Page Interactive Data File (Inline XBRL).